NASDAQ
Pasithea Therapeutics Corp. (KTTA)
♥ 284 Thanks from members
Pasithea Therapeutics Corp. (KTTA) faces mixed market sentiment, driven by clinical progress for its macrocyclic MEK inhibitor PAS-004 in advanced cancers and neurofibromatosis, weighed heavily against Nasdaq minimum bid price compliance issues and a low equity valuation.